MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Editas Medicine, Inc. - Common Stock (NQ:EDIT)

3.340 -0.120 (-3.47%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Editas Medicine, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
7 Mighty Healthcare Stocks Changing the Game of Medicine ↗
Thanks to the permanent relevance of medical innovations, investors ought to consider looking at these healthcare stocks. 
Via InvestorPlace
News headline image
Down 88%, Could Editas Medicine Be a Good Investment Now? ↗
The past few years have been difficult ones, but shares of the gene editor are far more attractive now that a CRISPR medicine has passed regulatory hurdles. 
Via The Motley Fool
News headline image
3 Stocks to Buy in the Booming Field of Gene Editing ↗
As the promise of gene editing moves closer to being a reality, these gene editing stocks have the opportunity for long-term gains. 
Via InvestorPlace
News headline image
Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics ↗
These two are at very different stages of the clinical trials process. 
Via The Motley Fool
News headline image
The Latest Analyst Ratings for Editas Medicine ↗
 
Via Benzinga
News headline image
A Preview Of Editas Medicine's Earnings ↗
 
Via Benzinga
News headline image
Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
2 gene-editing stocks reshaping hereditary disease treatments
Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal 
Via MarketBeat
News headline image
Editas Just Caught a Break Thanks to Vertex Pharmaceuticals ↗
Editas isn't out of the woods yet, but it's better off than before. 
Via The Motley Fool
News headline image
Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Bull Of The Day: Crispr Therapeutics ↗
CRISPR Therapeutics (CRSP) just made history on Friday with the first FDA-approved gene-editing medicine based on the Nobel Prize-winning discovery that targets disease with the billion-year old... 
Via Talk Markets
News headline image
1 Promising Stock Down 66% That Could Skyrocket in 2024 ↗
Financial results aren't what matters most right now for this company. 
Via The Motley Fool
News headline image
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead. ↗
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach. 
Via The Motley Fool
News headline image
If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names ↗
As we head into December 2023, some of the hottest investment opportunities can be found in these biotech stocks. 
Via InvestorPlace
News headline image
Hidden Gems for Hefty Returns: 3 Stocks Set to Double Your Wealth Next Year ↗
Investors may want to strongly consider this new list of stocks to buy that could double in 2024. Check out these hidden gems. 
Via InvestorPlace
News headline image
The 3 Best Gene Editing Stocks on the Frontier of Medicine ↗
Some of the best gene editing stocks could soon see a massive boost from these two massive catalysts in December. 
Via InvestorPlace
News headline image
2 Beaten-Down Growth Stocks That Could Rocket 42% to 67% Higher, According to Wall Street ↗
Investment bank analysts are pounding the table on these stocks, but are they right for your portfolio? 
Via The Motley Fool
News headline image
3 Long-Term Growth Stocks Analysts Are Bullish On ↗
Here are three long-term growth stocks for your consideration if you’re looking to take a long position in a new name or two. 
Via InvestorPlace
News headline image
3 Biotech Stocks That Are Betting on the Future of Gene Editing ↗
These three companies have gene editing therapies in late-stage clinical trials, making them promising biotech stocks to buy right now. 
Via InvestorPlace
News headline image
Why Fortinet Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers Benson Hill, Inc. (NYSE: BHIL) shares jumped 48.1% to $0.3740. 
Via Benzinga
News headline image
Expedia Group, Gartner, Cloudflare, Cardinal Health And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
News headline image
Earnings Scheduled For November 3, 2023 ↗
Companies Reporting Before The Bell • Arcutis Biotherapeutics (NASDAQ:ARQT) is expected to report quarterly loss at $0.86 per share on revenue of $32.83 million. 
Via Benzinga
News headline image
Editas Medicine Announces Third Quarter 2023 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient ↗
This gene-editing pioneer could make history this week. But shareholders should remain focused on the long term. 
Via The Motley Fool
News headline image
Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
3 Gene Editing Stocks to Generate Super-Charged Gains ↗
As things progress, such techniques may be able to knock out every disease known, creating massive opportunity for gene-editing stocks. 
Via InvestorPlace
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023 ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story